Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CD69 | Q07108 | 4/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147168 | 0.87 | KMT2A (0.51) | KMT2ACD69ALOX15SMN1; SMN2TSHR | |
| SCHEMBL18668604 | 0.85 | CES2 (0.43) | KMT2ACD69 | |
| SCHEMBL23111641 | 0.84 | PTGDR2 (0.57) | KMT2ACD69ALOX15SMN1; SMN2TSHR | |
| SCHEMBL6745272 | 0.84 | SMN1; SMN2 (0.60) | KMT2ACD69ALOX15SMN1; SMN2TSHR | |
| SCHEMBL2599614 | 0.82 | KMT2A (0.48) | KMT2ACD69SMN1; SMN2TSHRKDM4E | |
| SCHEMBL9722723 | 0.82 | KMT2A (0.44) | KMT2ACD69ALOX15ALDH1A1 | |
| SCHEMBL19983110 | 0.82 | KMT2A (0.40) | KMT2ACD69 | |
| SCHEMBL4832334 | 0.79 | SMN1; SMN2 (0.43) | KMT2ASMN1; SMN2TSHRLMNAKDM4E | |
| SCHEMBL29757370 | 0.78 | L3MBTL1 (0.61) | KMT2AALOX15SMN1; SMN2LMNAKDM4E | |
| SCHEMBL257482 | 0.78 | L3MBTL1 (0.61) | KMT2AALOX15SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-3321252-B1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | PUBLIC UNIV CORP YOKOHAMA CITY UNIV (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-0623605-A2 | Substituted piperazines as antiretroviral medicaments | BAYER AG (DE) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | DNPEP, ASPH, CTSC | KMT2A 1800/4885CD69 4235/4885ALOX15 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.